This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Ofatumumab
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
* Major Indication: Chronic Lymphocytic [[Cancer|Leukemia]] | * Major Indication: Chronic Lymphocytic [[Cancer|Leukemia]] | ||
* Drug Class: Anti-CD20 [[Monoclonal Antibody]] | * Drug Class: Anti-CD20 [[Monoclonal Antibody]] | ||
| - | * Date of FDA Approval: 2009 (2023) | + | * Date of FDA Approval (Patent Expiration): 2009 (2023) |
* 2009 Sales: $3.1 Billion | * 2009 Sales: $3.1 Billion | ||
* | * | ||
Revision as of 07:32, 14 December 2010
|
Better Known as: Arzerra
- Marketed By: Genmab & GlaxoSmithKline
- Major Indication: Chronic Lymphocytic Leukemia
- Drug Class: Anti-CD20 Monoclonal Antibody
- Date of FDA Approval (Patent Expiration): 2009 (2023)
- 2009 Sales: $3.1 Billion
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
References
